Chemical Nameburosumab-twza
Dosage FormInjectable (subcutaneous; 10 mg/mL, 20 mg/mL, 30 mg/mL)
Drug ClassMonoclonal antibodies
CompanyUltragenyx Pharm Inc
Approval Year2018


  • Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older.
Last updated on 10/22/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Crysvita (burosumab-twza) Prescribing Information2019Ultragenyx Pharm